A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

  • STATUS
    Enrolling By Invitation
  • participants needed
    5
Send
Updated on 19 February 2024

Summary

Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®. Betalutin® is made by using a new antibody, called lilotomab, and attaching a radioactive molecule (radioisotope) called Lutetium-177. The radioisotope Lutetium-177 may be more suitable for radioimmunotherapy than the radioisotopes that have previously been used for non-Hodgkin lymphoma. The Betalutin® binds to an area on the surface of the cancer cells called CD37. This therapy is intended to target the cancer cells with the radioactivity, thereby irradiating them inside the body.

Description


FAQ


Details
Condition non-Hodgkin lymphoma
Age 18years - 90years
Clinical Study Identifier01796171
Last Modified on19 February 2024

Eligibility

If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.